Methyl pyruvate protects a normal lung fibroblast cell line from irinotecan-induced cell death : Potential use as adjunctive to chemotherapy

The Warburg Effect, characterized by increased rate of glycolysis even under normoxic conditions, is one of the hallmarks of cancer. Relatively lower oxidative phosphorylation (OXPHOS) is also a characteristic feature in cancer cells. We hypothesized that interference with this phenomenon, by introducing exogenous pyruvate, would upset this cancer phenotype and boost the energy requirements of normal cells. We find that methyl pyruvate protects irinotecan-treated normal lung fibroblast cell line (MRC-5) probably by turning off the p53/p21 axis of the apoptotic pathways. When the MRC-5 fibroblasts recover in drug-free medium, the intrinsic apoptotic pathway is also turned off and the cells survive with no discernible exponential growth during the observation period. In contrast, the mere introduction of exogenous pyruvate kills the lung cancer cell line (A549). Although, functional p53 is important in the drug-induced cancer cell death, it is probably not essential because cancer cell lines with mutated p53 also die albeit less efficiently. We conclude that methyl pyruvate may preferentially kill cancer cells and protect normal cells during chemotherapy.

Errataetall:

ErratumIn: PLoS One. 2018 Apr 9;13(4):e0194260. - PMID 29630624

Medienart:

E-Artikel

Erscheinungsjahr:

2017

Erschienen:

2017

Enthalten in:

Zur Gesamtaufnahme - volume:12

Enthalten in:

PloS one - 12(2017), 8 vom: 26., Seite e0182789

Sprache:

Englisch

Beteiligte Personen:

Monchusi, Bernice [VerfasserIn]
Ntwasa, Monde [VerfasserIn]

Links:

Volltext

Themen:

3KJM65G5XL
7673326042
Antineoplastic Agents, Phytogenic
Apoptosis Regulatory Proteins
Camptothecin
Irinotecan
Journal Article
Methyl pyruvate
Protective Agents
Pyruvates
XT3Z54Z28A

Anmerkungen:

Date Completed 19.10.2017

Date Revised 02.12.2018

published: Electronic-eCollection

ErratumIn: PLoS One. 2018 Apr 9;13(4):e0194260. - PMID 29630624

Citation Status MEDLINE

doi:

10.1371/journal.pone.0182789

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM274705400